Anticholinergic antimuscarinic agents in the treatment of airways bronchoconstriction in children

Martinati, L. C.; Boner, Al

doi:10.1111/j.1398-9995.1996.tb00002.x

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Potential side effects of these β-sympathomimetic agents include tachycardia, hypokalemia, arrhythmias, hypertension, and hyperglycemia [45][46][47]. Inhaled anticholinergic compounds (eg, atropine, ipratropium) demonstrate similar benefits [41,48,49] with specific synergism between ipratropium bromide and salbutamol [50]. Side effects of these inhaled agents include tachycardia, decreased peristalsis, tremors, and drying of respiratory secretions [45].…”

Section: Bronchodilatorsmentioning

confidence: 99%

Lung Injury and Bronchopulmonary Dysplasia in Newborn Infants

Christou

Brodsky

2005

J Intensive Care Med

View full text Add to dashboard Cite

Bronchopulmonary dysplasia is the most common morbidity among surviving premature infants. Injury to the developing lung is the result of the interaction between a susceptible host and a number of contributing factors such as mechanical ventilation and infection. The resulting persistent impairment of pulmonary function and need for ongoing therapy are the underlying characteristics of bronchopulmonary dysplasia. Important insights into the pathogenesis of bronchopulmonary dysplasia have led to numerous therapies and preventive approaches. Although significant progress has been made, in order to further affect the incidence and severity of the disease, we need to further study (a) the genetically determined predisposing factors, (b) the relative contribution of the various pathogenetic pathways, and, most important, (c) how to best translate the knowledge gained from these studies into effective clinical approaches.

show abstract